Zum Hauptinhalt springen

Primärprävention von Herz- und Gefäßerkrankungen

Zuletzt bearbeitet: Zuletzt revidiert:
Zuletzt revidiert von:

  • Deutsche Gesellschaft für Allgemeinmedizin (DEGAM). Leitlinie: Hausärztliche Risikoberatung zur kardiovaskulären Prävention. S3. Stand 2017. www.degam.de 
  • NVL-Programm von BÄK, KBV, AWMF. Nationale VersorgungsLeitlinie Chronische KHK. AWMF-Leitlinie Nr. nvl-004, Stand 2013. www.awmf.org 
  1. The Emergency Risk Factors Collaboration. Separate and combined association of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011; : doi: 10.1016/S0140-6736(11)60105-0. DOI  
  2. Myint PK, Kwok CS, Luben RN. Body fat percentage, body mass index and waist-to-hip ratio as predictors of mortality and cardiovascular disease. Heart 2014. doi:10.1136/heartjnl-2014-305816 DOI  
  3. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929-934. PubMed  
  4. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 775. PubMed  
  5. Kavousi M, Elias-Smale S, Rutten JHW, et al. Evaluation of newer risk markers for coronary heart disease risk classification: A cohort study. Ann Intern Med 2012; 156: 438-44. Annals of Internal Medicine  
  6. Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379: 2053-62. PubMed  
  7. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012; 308: 796-803. Journal of the American Medical Association  
  8. Deutsche Gesellschaft für Allgemeinmedizin (DEGAM). Leitlinie: Hausärztliche Risikoberatung zur kardiovaskulären Prävention. S3. Stand 2017. www.degam.de  
  9. Dehghan M, Mente A, Rangarajan S, et al. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2018; 392: 2288-97. pmid:30217460. www.ncbi.nlm.nih.gov  
  10. van Wyk H, Davis RE, Davis JS. A critical review of low-carbohydrate diets in people with type 2 diabetes. Diabetes Med. 2016;33:148. www.ncbi.nlm.nih.gov  
  11. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013; 1: CD004816. Cochrane (DOI)  
  12. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65229 participants. Arch Intern Med 2010; 170: 1024-31. PubMed  
  13. Alpérovitch A, Kurth T, Bertrand M, et al. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ 2015; 350: h2335. doi:10.1136/bmj.h2335 DOI  
  14. Freitag M. Satintherapie bei älteren Patienten in der Primärprävention? Arzneiverordnung in der Praxis (AVP) Arzneimittelkommission der deutschen Ärzteschaft, AkdÄ, 2019. (vorab online) www.akdae.de  
  15. 35. Gemeinsamer Bundesausschuss (GBA). Anlage III – Übersicht über Verordnungseinschränkungen und -ausschlüsse in der Arzneimittelversorgung durch die Arzneimittel-Richtlinie und aufgrund anderer Vorschriften (§ 34 Absatz 1 Satz 6 und Absatz 3 SGB V; 2016 [zuletzt geprüft am:02.09.2016]. www.g-ba.de  
  16. Diao D, Wright JM, Cundiff DK, et al. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev 2012 Aug 15;8:CD006742 Cochrane (DOI)  
  17. Barnett H, Burrill P, Iheanacho I. Don't use aspirin for primary prevention of cardiovascular disease. BMJ 2010; 340: c1805. BMJ (DOI)  
  18. ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804988. PMID: 30146931 www.ncbi.nlm.nih.gov  
  19. Gaziano JM, Brotons C, Coppolecchia R et al.. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.. Lancet 2018; 392: 1036-1046. pmid:30158069 PubMed  
  20. McNeil JJ, Wolfe R, Woods RL et al . Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.. N Engl J Med 2018; 379: 1509-18. pmid:30221597 PubMed  
  21. Rothwell PM, Cook NR, Gaziano M, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018. pmid:30017552 www.ncbi.nlm.nih.gov  
  22. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013 Oct 23;310(16):1711-20. PubMed  
  23. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of Dietary, Circulating, and Supplement Fatty Acids With Coronary Risk: A Systematic Review and Meta-analysis. Ann Intern Med. 2014 Mar 18;160(6). doi: 10.7326/M13-1788 DOI  
  24. The ASCEND Study Collaborative Group: Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018. PMID: 30146932 www.ncbi.nlm.nih.gov  
  25. Abdelhamid AS, Brown TJ, Brainard JS et al.Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018. PMID: 30019766 www.ncbi.nlm.nih.gov  
  26. Christoffersen M, Frikke-Schmidt R, Schnohr P, et al. Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in generel population. BMJ 2011; 343: d5497. BMJ (DOI)  
  27. Sesso HD, Christen WG, Bubes V, et al. Multivitamins in the Prevention of Cardiovascular Disease in Men: The Physicians` Health Study II Randomized Controlled Trial. JAMA 2012 Nov 7; 308(17): 1751-60. PubMed  
  28. Myung SK, Ju W, Cho B, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 346: f10. BMJ (DOI)  
  29. Jorgensen T, Jacobsen RK, Toft U, et al. Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ. 2014 Jun 9;348:g3617. doi: 10.1136/bmj.g3617 DOI  
  • Günther Egidi, Dr. med., Arzt für Allgemeinmedizin, Bremen (Review)
  • Ingard Løge, spesialist allmennmedisin, universitetslektor, institutt for sammfunsmedisinske fag, NTNU, redaktør NEL